Vergelijking

Glepaglutide vs. Lanreotid

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Onderzoek (overig)

CAS-nr.

geen gegevens

108736-35-2

Molecuulmassa

geen gegevens

1096.34 g/mol

Halfwaardetijd

geen gegevens

Sequentie

geen gegevens

Werkingsmechanisme

Glepaglutide

As a GLP-2 receptor agonist, glepaglutide has a trophic effect on the intestinal mucosa, enlarging the absorptive surface and thereby improving intestinal uptake of nutrients and fluid.

Lanreotid

Lanreotide activates somatostatin receptors (chiefly SSTR2, additionally SSTR5), thereby suppressing the release of growth hormone, IGF-1 and various gastrointestinal and neuroendocrine hormones. It is metabolically far more stable than natural somatostatin.

Bewijsbasis

Hoogste bewijs

Humane RCT

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	Glepaglutide	Lanreotid
Duitsland	Niet goedgekeurd	Op recept
Verenigde Staten	Niet goedgekeurd	Op recept

Volledige vermeldingen

Glepaglutide

Volledige vermelding →

Lanreotid

Volledige vermelding →

Frequently asked questions

What is the difference between Glepaglutide and Lanreotid?: Glepaglutide is classified as "Onderzoek (overig)", while Lanreotid is classified as "Onderzoek (overig)". Glepaglutide: Glepaglutide is a long-acting GLP-2 analogue (Zealand Pharma) intended to reduce the need for parenteral support in short bowel syndrome. Lanreotid: Lanreotide is a synthetic cyclic octapeptide analog of somatostatin. It binds preferentially to the somatostatin receptors SSTR2 and SSTR5 and is approved for treating acromegaly and certain neuroendocrine tumours. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Glepaglutide or Lanreotid?: The highest available evidence level is "Humane RCT" for Glepaglutide and "Humane RCT" for Lanreotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Glepaglutide and Lanreotid in Germany and the United States?: Duitsland: Glepaglutide — Niet goedgekeurd, Lanreotid — Op recept. Verenigde Staten: Glepaglutide — Niet goedgekeurd, Lanreotid — Op recept. These are factual summaries with source and review date on the individual pages.

Country

Glepaglutide

Lanreotid

Duitsland

Niet goedgekeurd

Op recept

Verenigde Staten

Niet goedgekeurd

Op recept

Frequently asked questions

What is the difference between Glepaglutide and Lanreotid?

Glepaglutide is classified as "Onderzoek (overig)", while Lanreotid is classified as "Onderzoek (overig)". Glepaglutide: Glepaglutide is a long-acting GLP-2 analogue (Zealand Pharma) intended to reduce the need for parenteral support in short bowel syndrome. Lanreotid: Lanreotide is a synthetic cyclic octapeptide analog of somatostatin. It binds preferentially to the somatostatin receptors SSTR2 and SSTR5 and is approved for treating acromegaly and certain neuroendocrine tumours. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Glepaglutide or Lanreotid?

The highest available evidence level is "Humane RCT" for Glepaglutide and "Humane RCT" for Lanreotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Glepaglutide and Lanreotid in Germany and the United States?

Duitsland: Glepaglutide — Niet goedgekeurd, Lanreotid — Op recept. Verenigde Staten: Glepaglutide — Niet goedgekeurd, Lanreotid — Op recept. These are factual summaries with source and review date on the individual pages.